The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Effect of Tofacitinib on Live Vaccine Responses

The Effect of Tofacitinib on Live Vaccine Responses

February 26, 2016 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270Vaccination for the herpes zoster virus (HZV) in patients with rheumatoid arthritis (RA) starting tofacitinib appears to be both safe and useful, according to a late-breaking abstract from the 2015 ACR/ARHP Annual Meeting.1 Nearly one in three people in the U.S. develops HZV, or shingles, in their lifetime, and nearly 1 million cases of shingles are reported annually, according to the Centers for Disease Control and Prevention CDC. Tofacitinib, an oral Janus kinase inhibitor, and other disease-modifying anti-rheumatic drugs (DMARDs) can increase the risk  that the herpes zoster virus will reactivate and cause shingles in these patients.2

You Might Also Like
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
  • Herpes Zoster & Tofacitinib
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
Also By This Author
  • ACR Honors Contributions to Rheumatology

“It’s really important to try to prevent shingles in these people,” says lead author Kevin Winthrop, MD, MPH, an infectious disease specialist at Oregon Health & Science University in Portland. “We wanted to see if tofacitinib influenced the response to the vaccine.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the study, “Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo,” eligible patients 50 and older were administered live zoster vaccine and given either 5 mg tofacitinib twice daily or placebo two to three weeks post-vaccination with continuation of background methotrexate. The primary endpoint was the geometric mean fold rise (GMFR) assessment in varicella-zoster-virus (VZV)-specific IgG titer at six weeks post-vaccination. The secondary study endpoints included the proportion of patients achieving ≥1.5-fold rise in VZV-specific IgG titer at six weeks.

“Four to six weeks after vaccination, the responses were great,” Dr. Winthrop says. “They were right in the ballpark of what we’d expect, based on other studies of the vaccine. Results were not any different between the tofacitinib-treated and the placebo-treated patients. In the two- to three-week gap following vaccination, the immune response was clearly adequate—and going on tofacitinib at that point didn’t seem to affect the immune response of the vaccine.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Winthrop points out that one participant developed disseminated shingles from the vaccine two days after starting tofacitinib. However, in retrospect, it was the only patient in the study who lacked pre-existing immunity.

“It raises the question of whether or not—for people starting certain immunosuppressive therapies—we should check their immunity before giving the vaccine, ” Dr. Winthrop says. “That said, the vaccine is not labeled that way. It’s labeled [as] safe for anyone over the age of 50. It’s just assumed everyone has immunity.”

Richard Quinn is a freelance writer in New Jersey.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Winthrop K, Wouters A, Choy EH, et al. Assessment of immunogenicity of live zoster vaccination (Zostavax) in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo. Arthritis Rheumatol. 2015 Oct;67(s10): 1–4046. doi: 10.1002/art.39448.
  2. Delzell E. Having rheumatoid arthritis raises shingles risk: Learn why the disease and medications used to treat it can cause this painful condition. Arthritis Foundation.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis

You Might Also Like:
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
  • Herpes Zoster & Tofacitinib
  • GlaxoSmithKline’s Shingles Vaccine Gets Approval in Canada
  • Shingles Vaccination Not at Goal Levels for U.S. Seniors

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.